SCHEDULE 13G: Invus Public Equities Group Discloses 8.5% Stake in Abivax S.A.

Invus Public Equities, L.P. and its affiliated entities have disclosed a beneficial ownership of 8.5% in Abivax S.A., holding 5,403,985 ordinary shares.

Summary

• Invus Public Equities, L.P., along with its general partner Invus Public Equities Advisors, LLC, managing member Invus Global Management, LLC, Siren, L.L.C., and individual Raymond Debbane, collectively reported beneficial ownership of 5,403,985 ordinary shares of Abivax S.A.
• This aggregate holding represents 8.5% of Abivax S.A.'s outstanding ordinary shares.
• The calculation of the percentage is based on 63,347,837 shares outstanding as of December 31, 2024, as reported in Abivax S.A.'s Annual Report on Form 20-F filed on March 24, 2025.
• As of September 2, 2022, Invus Public Equities, L.P. directly held 1,557,360 ordinary shares of Abivax S.A.
• As of the filing date, April 11, 2025, Invus Public Equities, L.P. directly holds 5,403,985 shares.
• Each American Depositary Share (ADS) of Abivax S.A., quoted on the Nasdaq Global Market under the symbol 'ABVX', represents 1 ordinary share.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, presenting neutral information without explicit positive or negative sentiment.

Positives

• The disclosure indicates a significant and increased stake by a major investment group, Invus Public Equities, L.P., in Abivax S.A., which may signal confidence in the company's future prospects.
• Invus Public Equities, L.P. increased its direct holding from 1,557,360 shares as of September 2, 2022, to 5,403,985 shares as of April 11, 2025, demonstrating a substantial accumulation of shares.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. Such disclosures provide transparency regarding significant shareholder positions, which can be of interest to other investors tracking institutional activity in the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and its increase, which may influence market perception and investor confidence.

Key Dates

Keywords

Abivax S.A., Invus Public Equities, Beneficial Ownership, Schedule 13G, SEC Filing, Ordinary Shares, American Depositary Shares, ABVX, Nasdaq, Institutional Investor